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Objectives
 Describe the pathophysiology of cystic fibrosis  (CF)
 Discuss updates in therapeutic management for patients with 
acute and chronic CF
 Formulate appropriate counseling points for a CF patient 
What is Cystic Fibrosis?
 Progressive, genetic disease that causes persistent lung 
infections & limits the ability to breathe over time
 Characterized by early colonization & infection of the airways
 Produces buildup of mucus in the lungs, pancreas & other 
organs
Epidemiology
 More than 30,000 people in the United States living with CF
 ~1,000 new cases are diagnosed each year
 More than half the population is over the age of 18
 Frequently occurs in those of northern European ancestry
 Lung disease is the major cause of morbidity and mortality in 
patients with CF
Pathophysiology 
 Autosomal recessive genetic disorder
 Caused by mutations in the gene encoding for the CFTR 
protein on chromosome 7
 Absence or dysfunction of the CFTR results in dehydrated, 
thickened secretions that obstruct epithelium lined ducts 
resulting in tissue damage
 Affects all exocrine glands
McNally P. Cystic Fibrosis. Netter’s Pediatrics.2011;41:246-249. 








What is cystic fibrosis? Stories. https://www.yourgenome.org/facts/what-is-cystic-
fibrosis. Published January 25, 2016. Accessed January 3, 2019. 
CFTR Regulator Function 
 Largely expressed in the apical membranes of epithelial cells 
that line the cylindrical structures of tissues that secrete fluids 
rich in mucus & other proteins
 Belongs to family of transmembrane proteins called 
adenosine triphosphate (ATP) binding cassette transporters
 1° role is to transport anions through the apical membrane of 
epithelial cells creating an osmotic gradient for fluid secretion
 Function is to regulate: 
 Chloride channel in apical membranes 
 Epithelial sodium channels 
 HCO3
-
Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros. 2015;14:419-430. 
CFTR Mutations
 ~2,000 mutations have been identified in the CFTR gene since 
its discovery in 1989
 ~242 mutations have been confirmed to cause CF
 Mutation F508del accounts for 70% of all mutations 
• ~50% of patients worldwide are homozygous & 40% 
are heterozygous
 Mutations can be broadly classified into 6 categories 
Cystic Fibrosis Foundation patient registry 2015: annual data report. Bethesda: Cystic Fibrosis Foundation; 2016.
Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531.
CFTR Mutations








 Prenatal Screening 
 The American College of Obstetricians and Gynecologists 
recommends that pregnant women be offered screening 
for CFTR mutations
 Prenatal diagnostic tests include chorionic villus 
sampling & amniocentesis
 Newborn Screening 
 Florida Statute 383.14(5)
 All newborn screening programs rely on elevations 
of immunoreactive trypsinogen
Newborn Screening Program. Florida Department of Health. http://www.floridahealth.gov/programs-and-services/childrens-health/newborn-screening/nbs-disorder.html. 
Sweat Test 
 Gold standard
 Measurement of sweat Cl- by 
quantitative pilocarpine iontophoresis
 A sweat Cl- concentration > 60 
mmol/L indicates a diagnosis of CF
 A concentration of < 30 mmol/L 
indicates that CF is unlikely
Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, 
Southern KW, Marshall BC, Sosnay PR. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017 
Feb;181S:S4-S15.e1.PMID: 28129811
“Woe is the child who tastes salty from a kiss on the brow, for he is cursed, and 
soon must die."
Diagnosis: Testing: Sweat Test. Johns Hopkins Cystic 
Fibrosis Center. https://www.hopkinscf.org/what-is-
cf/diagnosis/testing/sweat-test/. Accessed January 3, 
2019.
Clinical Presentation 
 Manifestations of Cystic Fibrosis
 Gastrointestinal system: 
• Malnutrition 
• Meconium ileus 
 Endocrine system: 
• Cystic fibrosis-related diabetes 
 Reproductive system:
• Azoospermia in males 
• Reduced fertility in females  
 Respiratory system 
Shruti M. Paranjape, and Peter J. Mogayzel Jr Pediatrics in Review 2014;35:194-205
Respiratory system 
 Impaired mucociliary clearance resulting in thick sputum
 Respiratory compromise characterized by copious 
hyperviscous & adherent pulmonary secretions
 Development of polyps in the sinus cavity
 Chronic infections 
 Digital clubbing 
Mayo Clinic Q and A: Diagnosing cystic fibrosis. Mayo Clinic. https://newsnetwork.mayoclinic.org/discussion/mayo-
clinic-q-and-a-diagnosing-cystic-fibrosis/. Accessed January 3, 2019. 
Respiratory system
 The dominant pathology in the lung is inflammation 
generated by failure to clear microorganisms & generation of 
a toxic pro-inflammatory local microenvironment
 Airway secretions contain a complex bacterial flora
 Staphylococcus aureus, Haemophilus influenzae, 
& Pseudomonas aeruginosa
Pharmacological Treatment 
 Goals of therapy: 
 Improve symptoms 
 Minimize loss of lung function 
 Minimize adverse drug reactions due to acute treatment
 Effective airway clearance involves the use of a 
bronchodilator, a mucolytic medication & chest percussion







Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med. 2006;354:291-293. 
Dornase Alfa (Pulmozyme®)
 MOA: recombinant human deoxyribonuclease I (rhDNase)
 Hydrolyzes the DNA in sputum of CF patients & reduces 
sputum viscoelasticity
 Dose:  2.5 mg single-use ampule inhaled once daily using a jet 
nebulizer/compressor system 
 Ampules should be stored in their protective foil pouch under 
refrigeration & protected from light
 ADRs: Voice alteration, pharyngitis, rash, laryngitis, chest 
pain, conjunctivitis, rhinitis, dyspepsia & dyspnea
Pulmozyme [package insert]. South San Francisco, CA: Genentech, Inc; 2014.
Mechanism of Action: MOA
Adverse Drug Reaction: ADR
Hypertonic Saline 
 Sterile, preservative-free sodium chloride inhaled solution 
available in 3.5% & 7% strengths
 Indicated for ≥ 6 years old & those with an FEV1 ≥ 40% 
 MOA: Mucolytic agent 
 Restores moisture to pulmonary system
 ↑ hydration of airway surface liquid via osmotic flow 
 Dose: 4 mL/vial via inhalation BID 
 ADRs: Increased cough, sore throat & chest tightness
Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. A controlled trial of long-term inhaled hypertonic saline in 
patients with cystic fibrosis. N Engl J Med 2006;354:229–240. 
Mechanism of Action: MOA




Lumacaftor + Ivacaftor (Orkambi®)
Tezacaftor + Ivacaftor (Symdeko®)
Ivacaftor (Kalydeco®) 
 MOA: Potentiator of the CFTR protein 
 Facilitates increased chloride transport
 Baseline & follow-up ophthalmological exams are 
recommended in pediatrics initiating Ivacaftor
 Assess ALT & AST prior to initiation, every 3 months during 
the 1st year of treatment & annually thereafter
 ADRs: HA, oropharyngeal pain, URI, nasal congestion, 
abdominal pain, nasopharyngitis, diarrhea, rash, nausea & 
dizziness
Kalydeco (ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.
Headache: HA
Upper Respiratory Infection: URI
Ivacaftor (Kalydeco®) 
 Available as oral tablets for patients ≥ 6 years old & oral granules for 
patients 1-5 years of age   
 Once mixed, oral granules should be consumed within the hour 
 Should be taken with fat containing foods 
 Co-administration with:
 Strong CYP3A inducers: not recommended 
 Strong CYP3A inhibitors: dose should be reduced to one tablet or one 
packet of oral granules twice a week
Dosing Regimen 
Age ≥ 6 years 150 mg tablet PO every 12 hours 
Age 1-5 years and weighing 7 kg to < 14 kg One 50 mg packet PO every 12 hours 
Age 1-5 years and  weighing ≥ 14 kg One 75 mg packet PO every 12 hours 
Kalydeco (ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.
Gene mutations responsive to Ivacaftor (Kalydeco®)
E56K G178R S549R S977F F1074L 2789+5GA
P67L E193K G551D F1052V D1152H 3272-26AG
R74W L206W G551S K10607 G1244E 3849+10kbCT 
D110E R347H D579G A1067T S125IN
D110H R352Q 711+3AG G1069R D1270N
R117C A455E E831X R1070Q G1349D
R117H S549N S945L R1070W S1255P
Kalydeco (ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.
Lumacaftor + Ivacaftor (Orkambi®)
 Indicated for pts  > 2 years who are homozygous for the 
F508del mutation in the CFTR gene
 MOA: 
 Lumacaftor improves the conformational stability of F508del-CFTR
 Ivacaftor is a CFTR potentiator that facilitates increased Cl- transport
Orkambi [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; September 2016.
Lumacaftor + Ivacaftor (Orkambi®)
 Should be taken with fat containing foods 
 ADRs: dyspnea, nasopharyngitis, nausea, diarrhea, URI, 
fatigue, ↑ blood CPK, rash, flatulence, rhinorrhea & influenza
Dosing Regimen
Age 
2-5 years of age and weighing > 14 kg One lumacaftor 100 mg/ ivacaftor 125 mg packet of granules every 12 hours 
2-5 years of age and weighing ≥ 14 kg One lumacaftor 150 mg/ ivacaftor 188 mg packet of granules every 12 hours 
6-11 years of age Two lumacaftor 100 mg/ivacaftor 125 mg tablets every 12 hours
12 years and older Two lumacaftor 200 mg/ivacaftor 125 mg tablets every 12 hours 
Orkambi [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; September 2016. Creatinine Phosphokinase: CPK
Tezacaftor + Ivacaftor (Symdeko®)
 Indicated for pts > 12 years of age who are homozygous for the 
F508del mutation or who have > 1 mutation in the CFTR gene 
that is responsive to tezacaftor/ivacaftor
Gene mutations responsive to Tezacaftor + Ivacaftor (Symdeko®)
F508del R117C D579G K1060T 2789+5GA
E56K E193K 711+3AG A1067T 3272-26AG
P67L L206W E831X R1070W 3849+10kbCT
R74W R347H S945L F1074L
D110E R352Q S977F D1152H
D110H A455E F1052V D1270N
Symdeko [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; February 2018
Tezacaftor + Ivacaftor (Symdeko®)
MOA: 
 Tezacaftor: Facilitates cellular processing & trafficking of CFTR to 
↑ amount of mature CFTR protein delivered to the cell surface
 Ivacaftor: CFTR potentiator that facilitates increased Cl- transport
Symdeko [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; February 2018
Tezacaftor + Ivacaftor (Symdeko®)
 Packaged as tezacaftor 100 mg/ivacaftor 150 mg fixed dose 
combination tab & ivacaftor 150 mg tab
 Dose: One tab (tezacaftor 100 mg + ivacaftor 150 mg) in AM 
and one tab (ivacaftor 150 mg) in PM
 Should be taken with fat containing foods
 Requires dose reduction in pts with hepatic impairment &  
those taking concomitant CYP inducers or inhibitors
 ADRs: HA, nausea, sinus congestion & dizziness 
Symdeko [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; February 2018




Amikacin Liposome Inhalation Suspension (Arikayce®)
Azithromycin (Zithromax®) 
Aztreonam (Cayston®)
Tobramycin (TOBI Podhaler®, Bethkis®)
Cystic Fibrosis Foundation Patient Registry. 2017 Annual Data Report. Bethesda, Maryland. Cystic Fibrosis Foundation; 2018.
Pseudomonas aeruginosa
 Gram negative rod widely distributed in nature & commonly 
present in moist environments
 Most frequently encountered lung pathogen in CF
 ~80% of patients are chronically colonized by Pseudomonas 
aeruginosa by the age of 20
 Colonization & infection with Pseudomonas aeruginosa remains 
the most important contributor to CF morbidity & mortality
Amikacin Liposome Inhalation 
Suspension (Arikayce®)
 Approved in Sep. 2018 under the Accelerated Approval Pathway
 Criteria for indication: 
 Adults with Mycobacterium avium complex (MAC)
 Limited/no alternative treatment options 
 Failed to achieve negative sputum cultures after a minimum of 6 
consecutive months of a multidrug background regimen therapy 
 MOA: Disruption & inhibition of protein synthesis in the target 
bacteria by binding to the 30S ribosomal subunit
Arikayce [package insert]. Bridgewater, NJ: Insmed Incorporated; 2018. 
Amikacin Liposome Inhalation 
Suspension (Arikayce®)
 Dose: Once daily oral inhalation of the contents of one 590 
mg/8.4 mL Arikayce® vial
 To be used only with the Lamira™ Nebulizer System
 ADRs: Dysphonia, cough, bronchospasm, hemoptysis, 
musculoskeletal pain, fatigue/asthenia & exacerbation of 
underlying pulmonary disease
Arikayce [package insert]. Bridgewater, NJ: Insmed Incorporated; 2018. 
Azithromycin (Zithromax®) 
 MOA: Inhibits RNA-dependent protein synthesis at the chain 
elongation step by binding to the 50S ribosomal subunit
 Contains anti-inflammatory properties that may benefit CF patients 
 Exact mechanism in CF is still unknown 
 Dose: 
 < 40 kg: 250 mg three times weekly 
 ≥ 40 kg: 500 mg three times weekly 
 ADRs: Nausea, diarrhea, & wheezing 
Azithromycin (Zithromax®) 
 Treatment of pts with CF chronically infected with P. 
aeruginosa with azithromycin led to ↓ morbidity &  mortality
 Pulmonary function & nutritional status improved
 Pulmonary exacerbation rates decreased
 Emergence of macrolide-resistant nontuberculous 
mycobacteria is of concern when considering chronic 
azithromycin therapy
 MDs considering azithromycin therapy should assess patients 
with CF for nontuberculous mycobacteria before & every 6 
months after initiating azithromycin
Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756. 
Aztreonam (Cayston®)
 An aerosolized formulation of the monobactam antibiotic 
aztreonam & lysine
 Indicated to improve respiratory symptoms in CF pts ≥ 7 years 
old with Pseudomonas aeruginosa
 MOA:  Binds to penicillin-binding proteins of susceptible 
bacteria, which leads to inhibition of bacterial cell wall 
synthesis & death of the cell
McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., and Montgomery A.B.: Inhaled aztreonam lysine for 
chronic airway Pseudomonas aeruginosa in Cystic Fibrosis. Am J Respir Crit Care Med 2008; 178: pp. 921-928
Cayston[package insert]. Foster City, CA: Gilead Sciences Incorporated; 2014. 
Aztreonam (Cayston®)
 Dose: Inhale one single use vial (75 mg aztreonam) 
reconstituted with 1 mL of sterile diluent TID for a 28 day 
course, followed by 28 days off drug
 To be used only with the Altera® Nebulizer System
 ADRs:  cough, nasal congestion, wheezing, pharyngolaryngeal
pain, pyrexia, chest discomfort, abdominal pain & vomiting
Cayston[package insert]. Foster City, CA: Gilead Sciences Incorporated; 2014. 
Tobramycin (TOBI Podhaler®)
 MOA: Aminoglycoside antimicrobial that acts primarily by 
disrupting protein synthesis in the bacterial cell which 
eventually leads to cell death
 Dose: Inhalation of the contents of four TOBI Podhaler® 
capsules twice daily for 28 days, followed by 28 days off drug
 One capsule contains 28 mg tobramycin
 Capsules should be used with the Podhaler device only 
 ADRs: cough, dyspnea, pyrexia, oropharyngeal pain, 
dysphonia, hemoptysis, & HA
TOBI [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015
Tobramycin (Bethkis®)
 MOA: Aminoglycoside antimicrobial that acts primarily by 
disrupting protein synthesis in the bacterial cell which 
eventually leads to cell death
 Dose: One ampule BID by oral inhalation in repeated cycles of 
28 days on drug, followed by 28 days off drug
 One 4 mL ampule contains 300 mg tobramycin 
 Administered using a hand-held PARI LC PLUS Reusable Nebulizer with 
a PARI Vios Air compressor
 ADRs: ↓ FEV, rales, ↑ red blood cell sedimentation rate, & 
dysphonia
 Light sensitive 
 Store in refrigerator 
Forced Expiratory Volume: FEVBethkis [package insert]. Cary, NC: Chiesi, Inc.; 2017.
THE ROLE OF A PHARMACIST
The Role of a Pharmacist
 Identify potential drug interactions 
 Kalydeco , Symdeko, and Orkambi
• Substrates of CYP3A4
 Patient Counseling 
 Encourage adherence to medication regimen 
 Verify appropriate inhaler/nebulizer technique 
 Kalydeco, Symdeko, and Orkambi should be taken with high fat 
meals 
 Ensure correct antibiotic selection in the setting of an acute 
exacerbation 
 Broad spectrum coverage 
 Two antipseudomonal agents 
Acute Exacerbations
 Diagnosis of an acute exacerbation is based on changes from 
an individual pt’s recent baseline health status
 Most exacerbations are not associated with the appearance 
of bacterial species or strains that are new to the pt
 Treatment: 
 Continuation of chronic treatment regimen 
 Glucocorticoids 
 Respiratory support 
 Systemic antibiotics 
Pharmacokinetics in CF Population
 Large volumes of distribution 
 Enhanced metabolic clearance 
 Increased risk for antimicrobial resistance 
 Difficulty with lung tissue penetration 
Great difficulty in attaining & maintaining 
therapeutic drug concentrations! 







Mogayzel PJ Jr, et al. Am J Respir Crit Care Med. 2013;187(7):680-689.
WHAT’S NEXT?
The Future of CF
New Therapies
 CF care has largely focused on the downstream effects of 
CFTR dysfunction
 New therapies aim to treat the underlying abnormality
 CF has among the highest number of gene-therapy trials
 CFTR pharmacotherapy: 
 CFTR gene mutations have different functional consequences
 Must target the distinct classes of mutation
 Treating the early & root causes of CF will improve outcomes 
& reduce the burdens of treatment
New Therapies
 Introduction of CFTR modulators has revolutionized CF care
 Drug screening campaigns have identified agents capable of 
suppressing CFTR nonsense alleles, augmenting potentiator
activity & further promoting F508del correction
 Advancement of new drugs that address specific CFTR defects 


























VX-445 + tezacaftor + ivacaftor
VX-659 + tezacaftor + ivacaftor
Inhaled Mannitol (Bronchitol®)
Inhaled Levofloxacin (Quinsair®)
Vancomycin Inhalation Powder 
(AeroVanc®)
Summary 
 CF is a disease state resulting from a dysfunction in the CFTR
 Multiple organ systems are affected in CF individuals
 Mortality is most commonly due to chronic organ damage or 
resistant pulmonary infections
 Breakthrough in CF treatment focuses on treating the basic 
defect of the disease: CFTR dysfunction 
Test Your Knowledge
True or False?
 The most common cause of pneumonia in patients with cystic 
fibrosis is burkholderia cepacia. 
 Inhaled antibiotics, such as Aztreonam (Cayston®) and 
Tobramycin (TOBI®), should be administered last in a patient’s 
inhaled medication regimen after bronchodilators and other 
inhaled therapies.
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